Mediaspace scheduled maintenance: Aug 25, 2026 07:00 - 12:00 AM. During this time, videos will be temporarily unavailable. Check status updates.

Home

Person

Vanessa Baeriswyl

This person has left EPFL

About
Privacy
Disclaimer

Graph Chatbot

Related publications (4)

Page 1 of 1

Identification of target-binding peptide motifs by high-throughput sequencing of phage-selected peptides

Christian Heinis, Inmaculada Rentero Rebollo, Vanessa Baeriswyl, Michal Sabisz

High-throughput sequencing was previously applied to phage-selected peptides in order to gain insight into the abundance and diversity of isolated peptides. Herein we developed a procedure to efficiently compare the sequences of large numbers of phage-sele ...

Oxford Univ Press2014

Novel inhibitors of the enzyme activated factor xii (fxiia)

Christian Heinis, Jonas Alfred Karl Wilbs, Vanessa Baeriswyl, Simon Jan Middendorp

The present invention relates to a bicyclic inhibitor of the coagulation enzyme activated factor XII (FXIIa) comprising or consisting of the peptide (X1)(X2)(X3)n(X4)(X5)(X6)m(X7)(X9)l(X10)(X11)(X12)(X13)(X14)k(X15)(X16), wherein (X1) is present or absent ...

2016

A Synthetic Factor XIIa Inhibitor Blocks Selectively Intrinsic Coagulation Initiation

Christian Heinis, Alessandro Zorzi, Shiyu Chen, Vanessa Baeriswyl

Coagulation factor XII (FXII) inhibitors are of interest for the study of the protease in the intrinsic coagulation pathway, for the suppression of contact activation in blood coagulation assays, and they have potential application in antithrombotic therap ...

American Chemical Society2015

Polycyclic Peptide Therapeutics

Christian Heinis, Vanessa Baeriswyl

Owing to their excellent binding properties, high stability, and low off-target toxicity, polycyclic peptides are an attractive molecule format for the development of therapeutics. Currently, only a handful of polycyclic peptides are used in the clinic; ex ...

Wiley-V C H Verlag Gmbh2013